apitegromab
Asset
Selective inhibitor of latent myostatin activation preventing muscle atrophy
- Stage
- Phase 3
- Modality
- Antibody
- Target
- MSTN
- 1
- Indication
- 0
- Trials
- 1
- Developer
Indications
1Spinal muscular atrophy
Phase 3, businesswire.com, 8 Oct 2026
In the full profile
- Targets and what it contains1
- Owner and partners1
- Evidence for its targets2
- Competitors1
Every asset’s record: target, stage, trials and the evidence behind it.
Updated 10 Oct 2026, 1 source